Katsanos KH, Papadakis KA. Inflammatory bowel disease: Updates on molecular targets for biologics. Gut Liver 2017; 11:455-63.
Kotze PG, Underwood FE, Damião AOM, et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: A systematic review. Clin Gastroenterol Hepatol 2020; 18: 304-12.
Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: A prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol 2019; 114:107-15.
M'Koma AE. Inflammatory bowel disease: An expanding global health problem. Clin Med Insights Gastroenterol 2013; 6:33-47.
Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: Sustaining healthcare delivery into the 21st century. Clin Gastroenterol Hepatol 2020; 18:1252-60.
Malik TA. Inflammatory bowel disease: Historical perspective, epidemiology, and risk factors. Surg Clin North Am 2015; 95:1105-22.
Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31:1-20.
Vegh Z, Kurti Z, Lakatos PL. The epidemiology of inflammatory bowel diseases from West to East. J Dig Dis 2017; 18:92-8.
Martins AL, Volpato RA, Zago-Gomes MP. The prevalence and phenotype in Brazilian patients with inflammatory bowel disease. BMC Gastroenterol 2018; 18:87-93.
Torres EA, Cruz A, Monagas M, et al. Inflammatory bowel disease in Hispanics: The University of Puerto Rico IBD Registry. Int J Inflam 2012; 2012:1-5.
Juliao-Baños F, Kock J, Arrubla M, et al. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine (Baltimore) 2021; 100:1-10.
Calderón M, Minckas N, Nuñez S, et al. Inflammatory bowel disease in Latin America: A systematic review. Value Heal Reg Issues 2018; 17: 126-34.
Simian D, Fluxá D, Flores L, et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol 2016; 22:5267-75.
Yamamoto-Furusho JK, Sarmiento-Aguilar A, Toledo-Maurño JJ, et al. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15years (2000-2017). Medicine (Baltimore) 2019; 98:1-10.
Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastroenterol 2014; 5:63-76.
Chapdelaine A, Mansour AM, Trovanov Y, et al. Metabolite monitorigin to guide thiopurine therapy in systemic autoinmmune diseases. Clin Rheumatol 2017; 36:1341-8.
Torres J, Bonovas S, Doherty G, et al. ECCO Guideline/Consensus Paper ECCO Guidelines on therapeutics in Crohn's disease: Medical treatment. J Crohn's Colitis 2020; 14:4-22.
Manz M, Vavricka SR, Wanner R, et al. Therapy of steroid-resistant inflammatory bowel disease. Digestion 2012; 86(suppl):11-5.
Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:496-505.
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12:205-17.
Kaplan GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12:720-7.
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2020; 390:2769-78.
Vendrell R, Venegas HL, Pérez CM, et al. Differences in prevalence of inflammatory bowel disease in Puerto Rico between commercial and government-sponsored managed health care insured individuals. Bol Asoc Med P R 2013; 105:15-9.
Paredes Méndez J, Otoya Moreno G, Mestanza Rivas Plata AL, et al. Epidemiological and clinical characteristics of inflammatory bowel disease in a tertiary referral hospital in Lima-Peru [Características epidemiológicas y clínicas de la enfermedad inflamatoria intestinal en un hospital de referencia de Lima-Per_u]. Rev Gastroenterol Peru 2016; 36:209-18.
Yamamoto-Furusho JK, Sarmiento-Aguilar A, Toledo-Mauriño JJ, et al. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15years (2000-2017). Medicine (Baltimore) 2019; 98:1-10.
Afzali A, Cross RK. Racial and ethnic minorities with inflammatory bowel disease in the United States: A systematic review of disease characteristics and differences. Inflamm Bowel Dis 2016; 22:2023-40.
Barnes EL, Nowell WB, Venkatachalam S, Dobes A, Kappelman MD. Racial and ethnic distribution of inflammatory bowel disease in the United States. Inflamm Bowel Dis 2021; izab219. doi:10.1093/ibd/izab219.
King JA, Underwood FE, Panaccione N, et al. Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: A population-based study of countries in the Organisation for Economic Co-operation and Development. Lancet Gastroenterol Hepatol 2019; 4:287-95.
Galoosian A, Rezapour M, Liu B, Bhuket T, Wong RJ. Race/Ethnicityspecific disparities in in-hospital mortality and hospital charges among inflammatory bowel disease-related hospitalizations in the United States. J Clin Gastroenterol 2020; 54:e63-72.
Tenailleau QM, Lanier C, Gower-Rousseau C, Cuny D, Deram A, Occelli F. Crohn's disease and environmental contamination: Current challenges and perspectives in exposure evaluation. Environ Pollut 2020; 263:1-14.
Ciaponni A, Virgilio SA, Berrueta M, et al. Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study. PLoS One 2020; 15:1-17.
Yu H, Maclsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther 2018; 47:364-70.
